文献速递腹部心血管技术与安全PETCT

外源性腺苷刺激肝动脉缓冲反应:肝脏静息/负荷灌注成像

Stimulation of the hepatic arterial buffer response using exogenous adenosine: hepatic rest/stress perfusion imaging.
PubMed 文献 · Eur Radiol · 2020-06-27

研究在心肌灌注成像患者中测量肝动脉灌注,开发肝动脉静息/负荷灌注成像,并比较腺苷或瑞加腺苷诱导的脾灌注与肝动脉灌注变化和心肌血流变化的关系。腺苷和瑞加腺苷后心肌血流与肝动脉灌注均增加但变化不相关;腺苷后脾灌注和肾灌注下降,瑞加腺苷后两者增加。肝动脉灌注对腺苷的反应可能成为评估肝病肝动脉血流动力学的新方法。

要点

  • 腺苷负荷后肝动脉灌注增加,变化幅度有时很大。
  • 肝动脉灌注变化与心肌血流变化不相关,不能以脾或肝动脉反应判断负荷是否充分。
  • 静息脾灌注与肝脏脂肪负荷相关,腺苷诱导的肝动脉灌注变化也与肝脏脂肪相关。

诊断标准与关键数值

  • 腺苷负荷后心肌血流和肝动脉灌注平均变化分别为1.1和0.8([负荷-静息]/静息),两者变化不相关。
  • 瑞加腺苷负荷后心肌血流和肝动脉灌注平均变化分别为1.4和0.6。
  • 腺苷后脾灌注变化-0.48、肾灌注变化-0.26,均下降。
  • 腺苷后脾灌注变化与心肌血流变化正相关(r=0.36;p=0.015),与肝动脉灌注变化不相关。
  • 瑞加腺苷后脾灌注变化0.2、肾灌注变化0.2,均增加;脾灌注变化与心肌血流变化(r=0.39;p=0.025)及肝动脉灌注变化(r=0.39;p=0.02)相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The hepatic arterial buffer response is a mechanism mediated by adenosine whereby hepatic arterial perfusion (HAP) increases when portal flow decreases, and is implicated in liver disease. The first study aim was to measure HAP in patients undergoing myocardial perfusion imaging (MPI), thus developing hepatic arterial rest/stress perfusion imaging (HAPI). The second aim was to compare adenosine-induced changes in splenic perfusion (SP) and HAP with corresponding changes in myocardial blood flow (MBF).

METHODS: Patients had MPI with 82Rb PET/CT using adenosine (n = 45) or regadenoson (n = 33) for stressing. SP and HAP were measured using a first-pass technique that gives HAP rather than total hepatic perfusion. Renal perfusion (RP) was also measured.

RESULTS: Mean MBF and HAP increased after both adenosine ([stress-rest]/rest 1.1 and 0.8) and regadenoson (1.4 and 0.6), but the respective changes did not correlate. After adenosine, SP (- 0.48) and RP (- 0.26) both decreased. The change in SP correlated positively with the change in MBF (r = 0.36; p = 0.015) but did not correlate with change in HAP. After regadenoson, SP (0.2) and RP (0.2) both increased. The changes in SP correlated with the changes in MBF (r = 0.39; p = 0.025) and HAP (r = 0.39; p = 0.02). Changes in RP correlated with changes in HAP (r = 0.51; p = 0.0008) but not MBF. Resting SP (r = 0.32; p = 0.004), but not resting HAP, correlated with hepatic fat burden. Adenosine-induced change in HAP also correlated with hepatic fat (r = 0.29; p = 0.05).

CONCLUSION: HAPI could be a useful new hepatic function test. Neither splenic 'switch-off' nor hepatic arterial 'switch-on' identifies adequacy of stress in MPI.

KEY POINTS: • This article describes a new method for assessing arterial perfusion of the liver and its capacity to respond to an infusion of adenosine, a substance that normally 'drives' hepatic arterial flow. • Hepatic arterial flow increased in response to adenosine, sometimes dramatically. Adenosine is already used clinically to stimulate myocardial blood flow in patients with suspected coronary disease, but the increase in flow did not correlate with the corresponding increase in hepatic arterial flow. • Analogous to the use of adenosine in the myocardium, the increase in hepatic arterial flow in response to adenosine has the potential to be a new clinically useful method for the evaluation of hepatic arterial haemodynamics in liver disease.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Keramida G, Gregg S, Peters AM, et al. Stimulation of the hepatic arterial buffer response using exogenous adenosine: hepatic rest/stress perfusion imaging. Eur Radiol. 2020. PMID: 32594209. doi:10.1007/s00330-020-06984-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。